<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247906</url>
  </required_header>
  <id_info>
    <org_study_id>721-TMA-EA</org_study_id>
    <nct_id>NCT04247906</nct_id>
  </id_info>
  <brief_title>Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab</brief_title>
  <official_title>Single Patient Expanded Access Treatment Plan (EAP; Also Known As A Compassionate Use Plan) To Provide Patients Access To The Investigational Product Narsoplimab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeros Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Impatients N.V. trading as myTomorrows</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Omeros Corporation</source>
  <brief_summary>
    <textblock>
      The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated
      thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with
      narsoplimab based on the medical judgement of their respective physicians.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Narsoplimab</intervention_name>
    <other_name>OMS721</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Patient (adult or pediatric) must have undergone allogeneic or autologous
             hematopoietic stem cell transplant (HSCT)

          -  Patient must be capable of understanding an informed consent form (ICF) or the parent
             or legal guardian of the patient is able to understand and sign a written ICF prior to
             the initiation of any treatment procedures.

          -  Patient must have HSCT- TMA defined as having thrombocytopenia and evidence of
             microangiopathic hemolytic anemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>My Tomorrows</last_name>
    <phone>+31 885253888</phone>
    <email>omerosmedical@mytomorrows.com</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombotic Microangiopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

